Immunocore Holdings (IMCR) Accumulated Expenses (2019 - 2026)

Immunocore Holdings (IMCR) has reported Accumulated Expenses for 8 consecutive years, with $207.4 million the latest figure, recorded in Q1 2026.

• Quarterly Accumulated Expenses rose 75.25% year-over-year to $207.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $207.4 million (up 75.25% YoY) and the FY2025 annual result came in at $219.7 million, up 18.44% from the prior year.
• Accumulated Expenses fell to $207.4 million in Q1 2026 per IMCR's latest filing, from $219.7 million in the prior quarter.
• Over the last five years, Accumulated Expenses for IMCR reached as high as $219.7 million in Q4 2025 and fell as low as $62.6 million in Q3 2022.
• A 5-year average of $143.3 million and a median of $143.8 million in 2025 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Accumulated Expenses jumped 98.29% — and 2025, when it fell 26.51%.
• Year by year, Accumulated Expenses stood at $73.2 million in 2022, then soared by 63.73% to $119.8 million in 2023, then jumped by 54.82% to $185.5 million in 2024, then climbed by 18.44% to $219.7 million in 2025, then retreated by 5.62% to $207.4 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $207.4 million, $219.7 million, and $144.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.